Latest News
Tiziana Announces Initiation of a Phase 1 Clinical Trial with Orally Administered Foralumab, a Fully Human anti-CD3 monoclonal antibody, in Healthy Volunteers
04 December 2019
London/New York, 4 December 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a clinical-stage biotechnology company focused on developing innovative therapeutics for inflammatory diseases and cancers, is pleased to announce initiation of a Phase I clinical trial...
Issue of equity and directorate change
20 November 2019
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
New York/London, 20 November 2019 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative...
Issue of convertible unsecured loan notes with warrants attached to raise £1,434,000
01 November 2019
Change to ADS ratio
30 October 2019
Interim Results for the Six Months Ended 30 June 2019: Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need
30 September 2019
London, 30 September 2019 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six...
Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers.
16 September 2019